IBCN 2017: Focus on biomarker driven clinical trial design in bladder cancer

Lisbon, Portugal (UroToday.com) Thomas Flaig from University of Colorado, Denver, CO presented research regarding use of biomarker driven clinical trial design. SWOG 8710 noted 38% v 15% pT0 for patients who did versus did not undergo neoadjuvant chemotherapy (NAC) followed by radical cystectomy. The COXEN is a gene expression model (GEM) in order to predict treatment outcome in patient treated with gemcitabine/cisplatin (GC) versus methotrexate/vinblastine/Adriamycin/cisplatin (MVAC) followed by radical cystectomy. S1314 is another trial assessing NAC GC versus dose dense-MVAC followed by radical cystectomy which received grant funding to support COXEN and miRNA work. Also proposals for genetic (DNA) and SNP analysis. First 100 samples have been obtained with 226 patient accruals and S1314 will be closed to accrual on December 1, 2017. Overall survival and pT0 will be assessed.

Speaker(s): Thomas Flaig, University of Colorado, Denver, CO

Written by: Stephen B. Williams, M.D., Associate Professor, Division of Urology, The University of Texas Medical Branch, Galveston, TX. and Ashish M. Kamat, M.D. Professor, Department of Urology, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX., at the International Bladder Cancer Network - October 21, 2017- Lisbon, Portugal

Login